Tue. 12 Mar 2024, 6:32am ET
Benzinga
Biotech, News, Health Care, General
- Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses
- Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the highest increases in PC1 and PC2
- Cohort 3 fully enrolled with data readout anticipated in mid-2024; Cohort 4 screening to start in 2Q 2024